Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

ToeFX Light Therapy for Chronic Venous Leg Ulcers

13 novembre 2026 mis à jour par: Dr. Ahmed Kayssi

Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study

Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.

A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.

The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.

This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.

The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.

Aperçu de l'étude

Description détaillée

Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.

A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.

ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.

This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.

Type d'étude

Interventionnel

Inscription (Estimé)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Ontario
      • Toronto, Ontario, Canada, M4L 3Y3
        • East Toronto Vascular Clinic
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age 18 years or older
  • Able to attend weekly visits for up to 12 weeks
  • Chronic venous leg ulcer (CEAP C6) of the lower extremity
  • Ulcer duration of 4 weeks or more
  • Ulcer size between 1 cm² and 20 cm² at baseline
  • Receiving standard-of-care compression therapy, or eligible to initiate it
  • Able to provide informed consent and comply with study procedures

Exclusion Criteria:

  • Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
  • Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
  • Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
  • Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
  • Heavy exudate requiring negative-pressure wound therapy
  • Known photosensitivity or allergy to methylene blue or light-based therapies
  • Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
  • Pregnancy or lactation
  • Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
  • Participation in another interventional study within 30 days of screening

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Faisabilité de l'appareil
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: ToeFX Treatment

Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure

Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation

Autres noms:
  • ToeFX
  • ClearToe Serum

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Treatment adherence
Délai: Baseline through Visit 12/ end of treatment (up to 12 weeks)

Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions

Baseline through Visit 12/ end of treatment (up to 12 weeks)
Safety: Adverse Events
Délai: Baseline through Healing Confirmation Visit (up to 14 weeks)

Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs

Baseline through Healing Confirmation Visit (up to 14 weeks)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percent Change in Wound Area From Baseline
Délai: Baseline, week 4, week 8, and week 12

Percent change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12
Complete wound epithelialization
Délai: 12 weeks

Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician

12 weeks
Time to complete wound healing
Délai: 12 weeks

Time (days) from baseline to complete epithelialization

12 weeks
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Délai: Baseline to 12 weeks/ end of treatment

Change in wound bed characteristics measured using the BWAT

Baseline to 12 weeks/ end of treatment
Change in pain score
Délai: Baseline to 12 weeks/ end of treatment

Change in pain score (0-10 Numeric Rating Scale)

Baseline to 12 weeks/ end of treatment
Change in health-related quality of life
Délai: 12 weeks/ end of treatment

Change in EQ-5D-5L score

12 weeks/ end of treatment
Patient satisfaction
Délai: 12 weeks/ end of treatment

Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire

12 weeks/ end of treatment
Clinician feasibility
Délai: 14 weeks or earlier if wound healing

Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow

14 weeks or earlier if wound healing
Absolute Change in Wound Area From Baseline
Délai: Baseline, week 4, week 8, and week 12

Absolute change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 novembre 2026

Achèvement primaire (Estimé)

31 octobre 2027

Achèvement de l'étude (Estimé)

31 octobre 2027

Dates d'inscription aux études

Première soumission

13 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner